Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
07:00am, Friday, 28'th May 2021
PHILADELPHIA, May 28, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the Goldman S
Amicus, Bloomin' Brands, Seagate and More Friday Afternoon Analyst Calls
12:26pm, Friday, 21'st May 2021
With the trading day more than halfway over, the markets were somewhat mixed going into the weekend.
Amicus Therapeutics Announces Upcoming Presentations at the 16th International Congress on Neuromuscular Diseases
07:00am, Friday, 21'st May 2021
PHILADELPHIA, May 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 16th Inter
Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y
12:47pm, Tuesday, 11'th May 2021
Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2021 Results - Earnings Call Transcript
11:02am, Monday, 10'th May 2021
Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q1 2021 Results - Earnings Call Transcript
Recap: Amicus Therapeutics Q1 Earnings
08:01am, Monday, 10'th May 2021
Shares of Amicus Therapeutics (NASDAQ:FOLD) rose 0.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 28.57% over the past year to ($0.25), wh
Amicus Therapeutics to Present at Upcoming Investor Conferences in May 2021
07:00am, Friday, 07'th May 2021
PHILADELPHIA, May 07, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the fo
Amicus Therapeutics Concludes Pre-BLA Meeting With FDA For AT-GAA In Pompe Disease
08:30am, Monday, 03'rd May 2021
Amicus Therapeutics Inc (NASDAQ: FOLD) has completed a Type B Pre-Biologics License Application (BLA) meeting with the FDA for AT-GAA (cipaglucosidase alfa co-administered with miglustat) for Pomp
Amicus Therapeutics Recognized as a Great Place to Work® in Europe
07:00am, Wednesday, 28'th Apr 2021
Great Place to Work® Certification in the United Kingdom, Spain, Italy and Germany Great Place to Work® Certification in the United Kingdom, Spain, Italy and Germany
Amicus Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
07:00am, Monday, 26'th Apr 2021
PHILADELPHIA, April 26, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, May 10, 2021 at 8:30
Why Amicus Therapeutics Stock Is Soaring Today
12:33pm, Wednesday, 14'th Apr 2021
Investors cheered an analyst's upgrade of the biotech stock.
Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2020 Results - Earnings Call Transcript
01:02pm, Monday, 01'st Mar 2021
Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2020 Results - Earnings Call Transcript
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates
09:07am, Monday, 01'st Mar 2021
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -12.50% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview for Amicus Therapeutics
10:10am, Friday, 26'th Feb 2021
Amicus Therapeutics (NASDAQ:FOLD) unveils its next round of earnings this Monday, March 01. Get prepared with Benzinga's ultimate preview for Amicus Therapeutics's Q4 earnings.
Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know
01:39pm, Monday, 22'nd Feb 2021
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
